Business
Shield Wins Gold at Titan Branding Awards
Shield Therapeutics plc has received a Gold award at the 2025 Titan Brand Awards for its rebranding of ACCRUFeR®, recognizing it as the Best Rebranding Effort and Best Healthcare Rebranding. This award highlights ACCRUFeR®'s successful transformation into a differentiated, patient-focused brand, contributing to its position as the number one branded prescription oral iron in the US iron deficiency/iron deficiency anemia market. The company views this as the initial step in its digital marketing strategy to drive further growth for ACCRUFeR®, which addresses a significant unmet need in a $2.3 billion market opportunity. Disclaimer*
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n\n \nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nShield Therapeutics Wins Gold at Titan Branding Awards for ACCRUFeR's Brand Transformation\n \nLondon, UK, December 11, 2025: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency announces that it has been awarded Gold at the 2025 Titan Brand Awards for Best Rebranding Effort, Best Healthcare Rebranding for ACCRUFeR®.\n \nThe Titan Brand Awards represent international recognition for outstanding achievements in branding, highlighting effective brand strategies, creative thinking, and strong communication that help organisations distinguish themselves in competitive markets. This prestigious recognition elevates ACCRUFeR® into the ranks of globally respected brands, both within the pharmaceutical industry and across broader sectors, underscoring its position as a trusted name on the world stage.\n \nAndy Hurley, CCO at Shield, commented: \"We are proud to receive the \"Best Rebranding Effort\" award for ACCRUFeR®, recognising the team's dedication to transforming ACCRUFeR®, into a highly differentiated, patient-focused brand. These efforts have enabled us to highlight the real impact of ACCRUFeR®, in the vastly prevalent ID/IDA market which is a serious condition with a significant unmet need for patients and HCPs. Our refreshed brand is contemporary, engaging, and underscores our commitment to improving lives, and has enabled ACCRUFeR® to be the #1 branded prescription oral iron in the US ID/IDA market. This is the first step in our digital marketing initiative driving growth of ACCRUFeR®.\"\n \n \nFor further information please contact:\n \n\n\n\n\nShield Therapeutics plc\n\n\nwww.shieldtherapeutics.com\n\n\n\n\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n\n\n+44 (0) 191 511 8500\[email protected]\n\n\n\n\n \nMarketing Agency\nReingold, Inc.\nAlexandra Gray, Public Relations Director\n \n\n\n+1 804 317 3352\[email protected]\n\n\n\n\nAbout Iron Deficiency and ACCRUFeR®/FeRACCRU®\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20...